Here, activated T-cells extravasate and migrate in response to gradients of rhCXCL11 and rhCXCL12. The described assay consists of a HUVEC-derived vascular tubule cultured under rocking flow, through which T-cells are added a collagenous stromal barrier, through which T-cells migrate and a chemoattractant/tumor (HCC0827 or NCI-H520) compartment. Presented here is a 3D chemotaxis assay, in a lung tumor-on-chip model with 3D endothelium (LToC-Endo), to address this need. While transwell and spheroid platforms have been employed, these models lack flow and endothelial barriers, and cannot faithfully model T-cell adhesion, extravasation and migration through 3D tissue. The correlation between increased T-cell infiltration and positive patient outcomes has motivated the search for therapeutics promoting T-cell infiltration.
Lung cancer is a leading cause of death worldwide, with only a fraction of patients responding to immunotherapy.
0 kommentar(er)
